To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
OE Original Cover

Platelet-rich Plasma (PRP) Versus Corticosteroid Injection for Painful Shoulder Conditions: Powered by OE M.I.N.D.

Cite This
+ Favorites
Cite This
+ Favorites
December 19, 2022

Platelet-rich Plasma (PRP) Versus Corticosteroid Injection for Painful Shoulder Conditions: Powered by OE M.I.N.D.

Vol: 5| Issue: 12| Number:3| ISSN#: 2563-559X

Authored By: Yaping Chang, Steve Phillips, Meng Zhu, Aiden Scholey & Mohit Bhandari on Behalf of OrthoEvidence.

Banner Image
  • OE M.I.N.D. contains data from 764 randomized controlled trials (RCTs) related to shoulder conditions with over 122,000 patients, and is a powerful and efficient tool to auto generate evidence reports regarding a clinical topic.
  • For shoulder conditions, corticosteroid injection demonstrates short-term (within 6 weeks) effectiveness in composite clinical outcomes and pain compared with platelet-rich plasma (PRP) injection.
  • PRP injection demonstrates superior outcomes in composite clinical outcomes compared with corticosteroid injection in follow-up duration of 3 to 6 months. There is no significant difference between PRP and corticosteroid injection in composite clinical outcomes in two follow-up periods: 6 weeks to 3 months, and 6 to 24 months.
  • Beyond 6 weeks post treatment, PRP injection shows superior outcomes in pain compared with corticosteroid injection.
  • There is no difference between PRP and corticosteroid injection in incidence of conversion to surgery or adverse events at the longest follow-up.
  • There are 10 studies aiming to recruit 628 patients currently ongoing studies that investigates the effects of PRP or corticosteroid injection in treating shoulder conditions using data from
  • In most published studies related to corticosteroid injection for shoulder conditions, incidence of adverse events and a follow-up of 6 months are reported.
  • Since 2011, the manufacturers that have published the most research associated with PRP or corticosteroid for shoulder conditions are Zimmer-Biomet, Pfizer, Regen Lab, Arthrex, Actavis and Terumo.
Shoulder pain affects 1 in 4 people and is associated with impared life quality and function in work and household activities (Luime et al., 2004). Lifetime prevalence of shoulder pain ranges from 7% to 67% and for individuals whose work involves more upper limb activity and whose age is over 50, the prevalence is even higher, up to 78% ...
OE OriginalPreview Image



Join the Conversation

Please Login or Join to leave comments.

Jeffrey Bogosian 2022-12-26

Orthopaedic Surgeon - United States

I would like to see a Study that repeats PRP at 6months to see if serial treatment is more effective.

Joseph Federico 2023-03-15

Physiotherapist - Canada

Thanks, OE. What is challenging and less helpful in this study is what we are truly comparing. As a physiotherapist, I would like to know if patients in these studies only received injections or if they were also receiving physical therapy - or at least provided with exercise. Receiving an injection is a passive approach to treating shoulder pain.  We know that an active approach is far better, and best practice. In my clinical experience, patients with recalcitrant pain who are receiving physical therapy may go for a cortisone injection AND continue physical therapy.  Anecdotally, recurrence is very low in my experience. A differentiator and selection criterion between cortisone and PRP is cost.  Is there enough data in this study, not knowing whether an active treatment was pursued, to advocate for the more costly [to the patient] PRP treatment? Best, Joseph Federico PT